{"id":4884,"date":"2019-10-09T13:00:35","date_gmt":"2019-10-09T11:00:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/recognize-emerging-players-in-the-lyme-disease-market-with-the-new-h2-2019-pipeline-review-researchandmarkets-com\/"},"modified":"2019-10-09T13:00:35","modified_gmt":"2019-10-09T11:00:35","slug":"recognize-emerging-players-in-the-lyme-disease-market-with-the-new-h2-2019-pipeline-review-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/recognize-emerging-players-in-the-lyme-disease-market-with-the-new-h2-2019-pipeline-review-researchandmarkets-com\/","title":{"rendered":"Recognize Emerging Players in the Lyme Disease Market with the New H2 2019 Pipeline Review – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Lyme Disease – Pipeline Review, H2 2019”<\/a> drug pipelines has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe Lyme Disease – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Lyme Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.\n<\/p>\n

\nThe Lyme Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lyme Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies \/Universities \/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.\n<\/p>\n

\nThe guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company\/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.\n<\/p>\n

\nScope of the report:<\/strong>\n<\/p>\n